John Tucker - Scpharmaceuticals President CEO, Director
| SCPH Stock | USD 3.45 0.16 4.86% |
CEO
Mr. John H. Tucker is re designated as President, Chief Executive Officer, Prior to that, from 2016 to 2017, Mr. Tucker served as chief executive officer of Algal Scientific. Before Algal Scientific, from 2014 to 2016, Mr. Tucker served as chief executive officer of Alcresta, a developer of enzymebased products for patients with acute and chronic diseases. Prior to Alcresta, from late 2013 to April 2014 Nelson Bach U.S., Mr. Tucker, Mr. Tucker worked at Nelson Bach U.S. as chief executive officer of its North American business. Prior to that, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospitalfocused specialty pharmaceutical company, from 2012 until the company was purchased by The Medicines Company in January of 2013. Mr. Tucker continued in his role at The Medicines Company through the transition into late 2013. Mr. Tucker joined Incline from AMAG Pharmaceuticals, a pharmaceutical company developing products that treat adults with iron deficiency anemia, where he was senior vice president, Commercial Operations in 2012. Prior to AMAG Pharmaceuticals, from 2007 to 2011, Mr. Tucker served as president, U.S. Operations at Basilea Pharmaceuticals, a multinational specialty biopharmaceutical company. Prior to Basilea, from 2002 to 2007, Mr. Tucker was executive vice president, Sales and Marketing at Indevus Pharmaceuticals, a specialty pharmaceutical company. Mr. Tucker also previously served at ALZA, a global pharmaceutical company, and at Johnson Johnson, including as senior director of trade relations, government sales and senior care since 2019.
| Age | 62 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 25 Mall Road, Burlington, MA, United States, 01803 |
| Phone | 617 517 0730 |
| Web | https://www.scpharmaceuticals.com |
John Tucker Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Tucker against Scpharmaceuticals stock is an integral part of due diligence when investing in Scpharmaceuticals. John Tucker insider activity provides valuable insight into whether Scpharmaceuticals is net buyers or sellers over its current business cycle. Note, Scpharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Scpharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Tucker over three months ago Acquisition by John Tucker of 100000 shares of Scpharmaceuticals subject to Rule 16b-3 | ||
John Tucker over six months ago Acquisition by John Tucker of 56025 shares of Scpharmaceuticals at 7.06 subject to Rule 16b-3 | ||
John Tucker over six months ago Acquisition by John Tucker of 56025 shares of Scpharmaceuticals at 7.06 subject to Rule 16b-3 |
Scpharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4202) % which means that it has lost $0.4202 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6689) %, meaning that it created substantial loss on money invested by shareholders. Scpharmaceuticals' management efficiency ratios could be used to measure how well Scpharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.55. The Scpharmaceuticals' current Return On Capital Employed is estimated to increase to -0.74. As of now, Scpharmaceuticals' Non Currrent Assets Other are increasing as compared to previous years. The Scpharmaceuticals' current Other Current Assets is estimated to increase to about 4.3 M, while Total Assets are projected to decrease to under 90.6 M.Similar Executives
| Found 6 records | CEO Age | ||
| Joseph MBA | Milestone Pharmaceuticals | 57 | |
| Eric MBA | Seres Therapeutics | 49 | |
| Maria Palasis | Lyra Therapeutics | 59 | |
| Dr MBA | Oncolytics Biotech | N/A | |
| Dietrich MBA | DiaMedica Therapeutics | 54 | |
| Tiago MD | Pasithea Therapeutics Corp | 48 | |
Management Performance
| Return On Equity | -1.67 | ||||
| Return On Asset | -0.42 |
Scpharmaceuticals Leadership Team
Elected by the shareholders, the Scpharmaceuticals' board of directors comprises two types of representatives: Scpharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scpharmaceuticals. The board's role is to monitor Scpharmaceuticals' management team and ensure that shareholders' interests are well served. Scpharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scpharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John PharmD, Senior Affairs | ||
| Rachael Nokes, Principal Accounting Officer | ||
| John Tucker, President CEO, Director | ||
| Katherine Taudvin, Director Relations | ||
| Michael Hassman, Senior Operations | ||
| Steve Parsons, Senior Commercial |
Scpharmaceuticals Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scpharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.67 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 125.65 M | ||||
| Shares Outstanding | 50.04 M | ||||
| Shares Owned By Insiders | 10.67 % | ||||
| Shares Owned By Institutions | 81.97 % | ||||
| Number Of Shares Shorted | 6.27 M | ||||
| Price To Book | 5.36 X |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.